Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) have been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $55.80.

A number of brokerages have recently weighed in on PTHS. Roth Mkm cut their price objective on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Zacks Research raised Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 24th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Piper Sandler initiated coverage on Pelthos Therapeutics in a research note on Friday, February 27th. They issued an “overweight” rating and a $48.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on Pelthos Therapeutics in a research note on Wednesday, April 1st. They issued an “overweight” rating and a $50.00 target price on the stock.

Institutional Trading of Pelthos Therapeutics

A number of hedge funds have recently modified their holdings of PTHS. Geode Capital Management LLC boosted its stake in shares of Pelthos Therapeutics by 31.9% in the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after buying an additional 3,295 shares during the last quarter. Knott David M Jr boosted its stake in shares of Pelthos Therapeutics by 215.5% in the fourth quarter. Knott David M Jr now owns 19,281 shares of the company’s stock worth $598,000 after buying an additional 13,169 shares during the last quarter. Persistent Asset Partners Ltd boosted its stake in shares of Pelthos Therapeutics by 150.0% in the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock worth $186,000 after buying an additional 3,604 shares during the last quarter. Diadema Partners LP boosted its stake in shares of Pelthos Therapeutics by 138.1% in the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after buying an additional 14,502 shares during the last quarter. Finally, Cantor Fitzgerald L. P. purchased a new stake in shares of Pelthos Therapeutics in the fourth quarter worth about $1,085,000. Hedge funds and other institutional investors own 77.96% of the company’s stock.

Pelthos Therapeutics Stock Performance

Shares of PTHS stock opened at $26.96 on Thursday. The company has a 50-day moving average price of $24.05. The company has a quick ratio of 1.86, a current ratio of 2.79 and a debt-to-equity ratio of 1.41. The firm has a market capitalization of $93.82 million, a price-to-earnings ratio of -1.31 and a beta of 3.29. Pelthos Therapeutics has a fifty-two week low of $9.00 and a fifty-two week high of $54.29.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($3.09) earnings per share for the quarter. The firm had revenue of $10.91 million during the quarter. Sell-side analysts forecast that Pelthos Therapeutics will post -11.7 earnings per share for the current year.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).